GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. Financials Guizhou Bailing Group Pharmaceutical Co., Ltd.
Equities
002424
CNE100000PY3
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5 CNY | -4.94% |
|
-22.60% | -38.35% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 11,404 | 11,236 | 6,928 | - |
| Enterprise Value (EV) 1 | 11,404 | 11,236 | 6,928 | 6,928 |
| P/E ratio | 81.6 x | -27 x | 15.2 x | 10.2 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 2.64 x | 1.27 x | 1.07 x |
| EV / Revenue | - | 2.64 x | 1.27 x | 1.07 x |
| EV / EBITDA | - | -30.2 x | 8.1 x | 6.3 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 3.26 x | 1.25 x | 1.11 x |
| Nbr of stocks (in thousands) | 1,397,598 | 1,385,502 | 1,385,502 | - |
| Reference price 2 | 8.160 | 8.110 | 5.000 | 5.000 |
| Announcement Date | 4/28/23 | 4/30/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 4,263 | 5,434 | 6,475 |
| EBITDA 1 | - | -372 | 855 | 1,100 |
| EBIT 1 | - | -484.4 | 560 | 827.8 |
| Operating Margin | - | -11.36% | 10.31% | 12.78% |
| Earnings before Tax (EBT) 1 | - | -493.1 | 548.1 | 823 |
| Net income 1 | 138.2 | -414.5 | 460.3 | 691.6 |
| Net margin | - | -9.72% | 8.47% | 10.68% |
| EPS 2 | 0.1000 | -0.3000 | 0.3300 | 0.4900 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/28/23 | 4/30/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -11.2% | 8.13% | 10.9% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | - | 2.490 | 4.010 | 4.500 |
| Cash Flow per Share 2 | - | 0.0900 | -0.5300 | 1.390 |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 4/28/23 | 4/30/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -38.35% | 959M | |
| +40.09% | 6.16B | |
| -16.34% | 4.46B | |
| -7.11% | 3.27B | |
| +5.14% | 3.2B | |
| -0.18% | 2.6B | |
| +47.93% | 1.98B | |
| -7.15% | 1.7B | |
| +0.67% | 1.66B | |
| -8.73% | 1.61B |
- Stock Market
- Equities
- 002424 Stock
- Financials Guizhou Bailing Group Pharmaceutical Co., Ltd.
